Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.

Alcoholism, clinical and experimental research - 1 Apr 2020

Hendershot Christian S, Dermody Sarah S, Wardell Jeffrey D, Zaso Michelle J, Kennedy James L, Stoner Susan A

Abstract excerpt

BACKGROUND: Initial evidence that OPRM1 genotype moderates the clinical response to naltrexone has not been replicated in prospective clinical trials. However, the use of traditional statistical analyses and clinical endpoints might limit sensitivity for studying pharmacogenetic associations, whereas the use of intensive daily assessments and person-centered analytic methods might increase sensitivity. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Drinking
Share to Alcoholism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Latent Class Analysis

Share to Medication Adherence

Share to Naltrexone

Share to Polymorphism, Genetic

Share to Random Allocation

Share to Receptors, Opioid, mu

Source

Open in PubMed Open full text

Identifiers

PMID: 32020635
DOI: 10.1111/acer.14300
PMCID: PMC8758337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.PMID 32020635Read ↗

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.Semantic proximity Read ↗

A prospective study of genetic factors, human laboratory phenotypes, and heavy drinking in late adolescence.Semantic proximity Read ↗

Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.Semantic proximity Read ↗

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Semantic proximity Read ↗

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.Semantic proximity Read ↗

A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.Semantic proximity Read ↗

The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.